Neuronal cell death contributes significantly to the pathology of traumatic brain injury (TBI) irrespective of the mode or severity of the injury. Activation of a pro-survival protein, Akt, is known to be regulated by an E3 ligase TRAF6 through a process of ubiquitination-coupled phosphorylation at its T308 residue. Here we show that upregulation of a pro-apototic protein, GADD34, attenuates TRAF6-mediated Akt activation in a controlled cortical impact model of TBI in mice. TBI induces the expression of GADD34 by stimulating binding of a stress inducible transcription factor, ATF4, to the GADD34 promoter. GADD34 then binds with TRAF6 and prevents its interaction with Akt. This event leads to retention of Akt in the cytosol and prevents phosphorylation at the T308 position. Finally, in vivo depletion of GADD34 using a lentiviral knockdown approach leads to a rescue of Akt activation and markedly attenuates TBI-induced cell death.
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Subject Category: Neuroscience Traumatic brain injury (TBI) is a devastating neurological injury associated with significant morbidity and mortality.
1 TBI can be classified as mild, moderate and severe based on severity of the injury. 2, 3 However, irrespective of the severity, the most common symptom following TBI is cell death. 4 One of the major features of TBI-induced cell death is an activation of NMDA receptors, [5] [6] [7] which leads to a robust increase in oxidative 8 and ER stress 9 in cells. It is well established that upregulation of ER stress potentiates its effect through an increase in phosphorylation of PKR-like ER-associated kinase (PERK) protein, which subsequently phosphorylates eIF2alpha to shut down global translation in cells. 10, 11 However, a few mRNA, such as the transcription factor ATF4, gain a selective advantage for translation under stress conditions. Intriguingly, recent work has further revealed that induction of oxidative stress in neurons leads to an increase of ATF4 in cells. 12 Upon selective activation of ATF4, several stress-related genes such as GADD34 are known to be upregulated. GADD34 is member of a family of GADD genes that are induced by DNA damage, growth factor deprivation and other forms of cell stress. 13 GADD34 has been shown to bind the eukaryotic serine/threonine phosphatase protein phosphatase 1 to direct eIF-2a dephosphorylation in vitro.
14, 15 Recent work suggests that the PERK is the major unfolded protein response-activated eIF-2a kinase in mammalian cells. 16 Phosphorylation of eIF-2a by PERK or GCN2, a distinct eIF-2a kinase that is activated by nutrient deprivation, 17 promotes the expression of GADD34, which then assembles an eIF-2a phosphatase that functions in a negative feedback loop to reverse eIF-2a phosphorylation and suppress the unfolded protein response.
14 Further work has shown that expression of GADD34 correlates with apoptosis induced by various signals, and its overexpression can initiate or enhance apoptosis. 18 A significant body of work has shown that TBI-induced cell death is also correlated with activation of Akt. 19 An important step of activation of Akt is its translocation from the cytosol to the plasma membrane, where it becomes activated in response to the stimulation of growth factor receptors at the cell surface. 20 Following growth factor-induced recruitment to the plasma membrane, Akt is phosphorylated at two conserved residues: (1) Thr308 within the active loop, 21, 22 and (2) Ser473 in the regulatory domain of Akt. 23, 24 The ubiquitin E3 ligase, TRAF6, can ubiquinate Akt and promote its translocation to the plasma membrane, where it becomes phosphorylated at the T308 position. In cells lacking TRAF6, it was shown that ubiquitination, membrane localization, activation and signaling of Akt is impaired in response to treatment with growth factors. 25 In the present study, we report for the first time that augmentation of GADD34 directly facilitates TBI-induced cell death in a controlled cortical impact model of TBI in mice. Oxidative or ER stress generated by TBI elicits a transcriptional increase in GADD34, enabling it to bind TRAF6 in competition with Akt. The binding of GADD34 to TRAF6 prevents TRAF6-mediated ubiquitination of Akt and subsequently prevents membrane translocation and phosphorylation of Akt at T308 position. In intact mice, depletion of GADD34 in the cerebral cortex reduces TBI-induced cell death, suggesting that GADD34's binding to TRAF6 is critical for TBI-induced neurotoxicity. The competition between GADD34 and TRAF6 for Akt binding may reflect a regulatory system that maintains cellular homeostasis in response to stressors such as TBI.
Results
Inactivation of Akt is associated with cell death following TBI. To characterize the neurotoxic effects of TBI, we monitored cell death through the TUNEL assay following 12, 24, 48 and 72 h (Supplementary Figure 1b,  Figure 1a ) using pericontusional cortex (Supplementary Figure 1a) following TBI. We found that, the number of TUNEL-positive cells was augmented significantly in mice after 12 and 24 h post TBI compared with sham controls (Figure 1a) . Moreover, consistent with findings by other investigators, 26, 27 we found that cell death was not further increased significantly after 24 h of TBI (Supplementary Figure 1b) .
As activation of pro-survival proteins such as Akt is known to have a neuroprotective effect against various brain injuries including TBI, we monitored phosphorylation of Akt following TBI at 12, 24 and 48 h after TBI (Figure 1b and Supplementary  Figure 1c) . We found that phosphorylation of Akt at T308 residue was significantly decreased at 12 and 24 h after TBI, which was evidenced both by western blot (Figure 1b ) and immunofluorescence microscopy ( Figure 1c ). We also found that phosphorylation of Akt at T308 was not further decreased at24 h following TBI (Supplementary Figure 1c) . However, phosphorylation of Akt at S473 was unaltered at 12 and 24 h after TBI (Supplementary Figure 1d) .
It is known that activation of Akt leads to phosphorylation of various anti-apoptotic proteins such as Foxo3a at S256 residue, 28, 29 BAD at S136 residue 30, 31 and GSK3b at S9 residue, 32, 33 which can minimize cell death. To determine whether the decrease in phosphorylation of Akt at the T308 position has any influence on phosphorylation levels of Foxo3a, Bad and GSK3b, we performed western blot hybridization to monitor their phosphorylation levels. The results revealed that phosphorylation of GSK3b, Foxo3a and Bad were decreased at 12 and 24 h after TBI (Figure 1d ). This finding suggests that the decrease in phosphorylation of Akt at T308 is sufficient to reduce its catalytic activity. Phosphorylation of Akt depends on its membrane translocation. To determine whether TBI has any influence on membrane translocation of Akt, we measured the levels of Akt in both the cytosol and membrane fraction. We found that membrane translocation of Akt was decreased significantly at 12 h after TBI, and it was further decreased at 24 h post TBI (Figure 1e) .
A decrease in TRAF6-mediated inactivation of Akt contributes to cell death following TBI. As TRAF6 is known to be a direct E3 ligase and essential for Akt ubiquitination, membrane translocation and phosphorylation, we examined the binding of TRAF6 and Akt in brain lysates following TBI. We found that the interaction between TRAF6 and Akt was markedly reduced at 12 and 24 h after TBI in mice (Figure 2a) . Activation of NMDAR is considered a major cause for neuronal death after brain injury. 5 In support of this contention, NMDAR antagonists were able to reduce cell death and improve outcome in animal models of TBI 34 and stroke. 35 To determine whether activation of NMDAR has any direct influence on Akt activation, we treated primary neurons in vitro with NMDA and found that NMDA significantly reduces interaction between TRAF6-Akt ( Supplementary  Figure 1e) , phosphorylation of Akt (Supplementary Figure 1f) and ubiquitination of Akt (Figure 2b ) that correlated with an increase in cell death (Figure 2c , compare bars 1 and 2). To establish whether the TRAF6-Akt cascade has any influence on NMDA-induced toxicity in primary neuronal cells, we depleted Akt in cells before treatment with NMDA. We found that NMDA-induced toxicity was increased significantly in cells depleted with Akt compared with cells treated with NMDA itself (Figure 2c , compare bars 3 and 4). To determine whether TRAF6 has any influence on NMDA-induced toxicity in cells, we overexpressed TRAF6 in control cells and in cells depleted with Akt. We found that cells overexpressing TRAF6 were able to restore NMDA-induced cell death to the extent of 85%. However, overexpression of TRAF6 in Akt-depleted cells was unable to restore NMDA-induced cell death ( Figure 2c , compare bars 3 and 5). Collectively, these findings suggest that TRAF6 provides neuroprotection against NMDA-induced cell death in an Akt-dependent manner.
GADD34 interacts with TRAF6 following TBI. An important question is how is the interaction between TRAF6 and Akt reduced following TBI? One possibility is that TRAF6 levels are attenuated following TBI. However we did not see any change in the level of TRAF6 at 12 or 24 h after TBI (Supplementary Figure 2a) . Another possibility is that TRAF6 may bind to other proteins in competition with Akt. To identify interacting proteins of TRAF6, co-immunoprecipitation coupled with mass-spectrometry analysis was performed on both sham and TBI mice samples. The results identified GADD34 as strongly interacting with TRAF6 in TBI samples. The binding was further confirmed by western blot hybridization ( Figure 3a ) and immunostaining procedure through confocal microscopy ( Figure 3b ). We also observed that TBI leads to an increase in the protein level of GADD34, which was evidenced by western blotting (Figure 3a , input level) and immunofluorescence staining (Figure 3c ). To see whether GADD34 was regulated transcriptionally, we performed RT-PCR analysis of GADD34. We found that mRNA levels of GADD34 were upregulated following TBI (Figure 3d ). GADD34 is transcriptionally upregulated by ATF4 under TBI condition. GADD34 is an inducible protein whose expression is regulated by a transcription factor ATF4. 10 Furthermore, both GADD34 and ATF4 can be induced by ER stress and oxidative stress. To confirm whether TBI leads to ER stress in the brain, we measured phospho-PERK and phospho-eIF2alpha protein levels. The results revealed that levels for both phospho-PERK and phospho-eIF2alpha were augmented at 12 and 24 h after TBI (Figure 4a ). TBI also led to an increase in oxidative stress, as evidenced by a significant increase in green fluorescence because of interaction between H2DCFDA with reactive oxygen species ( Figure 4b ). As ATF4 is known to be induced both by ER stress and oxidative stress, we examined protein levels of ATF4 by western blot analysis. We found that ATF4 levels were increased significantly at both 12 and 24 h after TBI (Figure 4c ). To determine whether an upregulation of ATF4 directly contributes to an increase in GADD34, we performed chromatin immunoprecipitation assay to detect ATF4 binding to the GADD34 promoter. We found that binding of ATF4 to GADD34 promoter was increased more than twofold after both 12 and 24 h of TBI compared with sham control (Figure 4d ).
To confirm that ER stress and oxidative stress can contribute directly to an increase in ATF4 levels, primary neurons in culture were pretreated with either an ER stress inhibitor (salubrinal) or an antioxidant (GSH) before treatment with the excitotoxic agent, NMDA. Treatment with NMDA led to an increase in both ATF4 and GADD34 levels, an effect that was blocked by pretreatment with either salubrinal or GSH (Figure 4e ). These findings suggest that the TBI-induced increase in oxidative and ER stress likely causes upregulation of GADD34 via transcriptional activation of ATF4.
TBI-induced upregulation of GADD34 prevents TRAF6-mediated activation of Akt. An important question is whether the interaction between GADD34 and TRAF6 has any influence on TRAF6-Akt interaction. To answer this question, we overexpressed GADD34 and TRAF6 in primary neurons, and determined the effect upon TRAF6-Akt interaction in the cells. The study revealed that GADD34 overexpression markedly diminished the binding of TRAF6 to NMDA. We observed that, cells lacking GADD34 restores interaction between TRAF6-Akt (Figure 5d ), phosphorylation of Akt (Figure 5e ) and attenuates NMDA-induced cell death (Figure 5f ). These findings suggest that GADD34 directly influences Akt phosphorylation and cell death by competitively altering its interaction with TRAF6.
Depletion of GADD34 rescues TBI-induced Akt inactivation and cell death in vivo. As we have shown that upregulation of GADD34 enhances NMDA-induced cell death via inactivation of Akt in cultured neurons in vitro, we were interested to determine whether endogenous depletion of GADD34 would modulate TBI-induced cell death in mice. To deplete GADD34 levels in intact mice, we utilized a viral vector system that delivers RNAi particles of GADD34 into the cerebral cortex. Immunohistochemical staining revealed that lentiviral particles of control and GADD34 RNAi display similar levels of expression in the cerebral cortex (Figure 6a ). We also monitored the expression level of GADD34 following sham and TBI conditions after administering lentiviral particles of GADD34 in brain. We found that GADD34 levels remain suppressed at 24 h either after sham or TBI (Figure 6b ). Mice overexpressing lentiviral particles of GADD34 RNAi exhibited a restored level of TRAF6-Akt interaction (Figure 6c ) and phosphorylation of Akt (T308) (Figure 6d ) at 24 h after TBI (e.g., more than 80% increased as compared with levels in mice overexpressing control RNAi). Of significant interest, depletion of endogenous GADD34 in mice brain significantly rescued TBI-induced cell death, as evidenced by a marked decrease in the number of TUNEL-positive cells (Figure 6e) . Thus, downregulation of GADD34 in the cerebral cortex leads to selective diminution of TBI-induced neurotoxicity in vivo.
Discussion
In the current study, we demonstrate for the first time that TBI-induced oxidative and ER stress augments TRAF6-GADD34 binding, which competes with the interaction of TRAF6 with Akt. The GADD34 competition prevents TRAF6-mediated ubiquitination and activation of Akt,, and thus blocks Akt neuroprotective activities in TBI ( Figure 7 ). TRAF6 is known to ubiquitinate Akt following growth factor treatment in cells. 25 Additional work has shown that TRAF6-mediated ubiquitination of Akt also occurs in the liver and is important for glucose uptake. Interestingly, TRAF6 ubiquitination acts through the K63-linked ubiquitination, but not the K48-linked ubiquitination. Thus, it does not affect the stability of Akt. 25 Secondly, Akt ubiquitination correlates well with Akt T308 phosphorylation and activation. Here, we have shown that TRAF6-mediated ubiquitination of Akt leads to phosphorylation at its T308 residue, which is important for its neuroprotection action against TBI. It is important to mention that TBI leads to a decrease in phosphorylation of Akt at the T308 position, whereas phosphorylation of Akt at the S473 residue remains unaltered. This is not so surprising, as it was previously shown that phosphorylation of these residues is independent from each other, and phosphorylation of each residue is sufficient to activate various downstream proteins in a context-dependent manner. 25, 36, 37 In agreement with these results, we found that the decrease in phosphorylation of Akt at the T308 residue in neurons leads to a decrease in phosphorylation of various downstream proteins such as Foxo3a, GSK3b and Bad, which are known to act as anti-apoptotic protein.
Previous work suggested that induction of GADD34 might allow the synthesis of pro-apoptotic proteins. Moreover, inhibition of eIF2a phosphatases has been reported to reduce ER stress-induced apoptosis. 38, 39 To determine the influence of the interaction between GADD34-TRAF6 on phosphorylation status of eIF2alpha, we depleted TRAF6 in primary neurons before treating with NMDA. The results revealed that the phosphorylation status of eIF2alpha remains unaltered in cells lacking TRAF6, as compared with control RNAi-treated cells (Supplementary Figure 2b) . This data provide evidence that GADD34 induces neurotoxicity independent of the eIF2alpha pathway following TBI.
In conclusion, our study provides evidence that upregulation of GADD34 following TBI leads to cell death in an Aktdependent manner. The molecular mechanism underlying this effect was shown to involve a competitive binding interaction of GADD34 with TRAF6, which prevents TRAF6-mediated activation of Akt in cells and augments neurotoxicity. Taken as a whole, our study provides new insight into the molecular mechanisms of cell death following TBI, which hopefully will facilitate development of new therapeutic strategies to ameliorate cell death following TBI and lead to improved functional outcome.
Materials and Methods
Stereotaxic injection of lentivirus particles into intact mice. Lentiviral particles of GADD34 RNAi were purchased from Santa Cruz (Santa Cruz, CA, USA) and administered in mouse brain according to the protocol described previously. 40 The Committee on Animal Use for Research and Education at Georgia Regents University approved all animal studies, in compliance with NIH guidelines. Adult male C57BL/6 mice (20-25 g; Charles River, Wilmington, MA, USA; Jackson Laboratory, Bar Harbor, ME, USA) were anesthetized with xylazine (8 mg/kg)/ketamine (60 mg/kg), and mounted on a stereotaxic frame (Stoelting, Wood Dale, IL, USA). The skull was exposed and 5.0 ml (10 7 -10 8 pfu/ml) of viral particles of GADD34 RNAi (n ¼ 9) protein was slowly injected into the cortex (anterior 0.5 mm, lateral 3.5 mm from bregma and ventral 1.0 mm relative to dura) over a period of 20 min using a 5.0 ml Hamilton syringe, and the needle was left in place for an additional 5 min. Seven days after viral infection, depletion of GADD34 in coronal sections was detected by western blot analysis and immunohistochemistry with an anti-GADD34 antibody (1 : 200). On day 8, TBI was performed as described previously. 41, 42 After each injection, mice were placed in a thermoregulated chamber maintained at 31 ± 0.5 1C and returned to their cages after full recovery from anesthesia. The rectal temperatures were monitored and maintained at 37.0 ± 0.5 1C during the experimental procedure.
TBI procedures. The Committee on Animal Use for Research and Education at Georgia Regents University approved all animal studies, in compliance with NIH guidelines. The procedure was done based on a protocol described by Kimbler et al. 42 Briefly, adult male C57BL/6 (Jackson Laboratory), mice were anesthetized with xylazine (8 mg/kg)/ketamine (60 mg/kg) and subjected to a sham injury or controlled cortical impact. Briefly, mice were placed in a stereotaxic frame (Amscien Instruments, Richmond, VA, USA) and a 3.5 mm craniotomy was made in the right parietal bone midway between bregma and lambda with the medial edge 12 mm lateral to the midline, leaving the dura intact. Mice were impacted at 4.5 m/s with a 20-ms dwell time and 12-mm depression using a 3-mm-diameter convex tip, mimicking a moderate TBI. Sham-operated mice underwent the identical surgical procedures, but were not impacted. The incision was closed with VetBond and mice were allowed to recover. Body temperature was maintained at 37 1C using a small animal temperature controller throughout all procedures (Kopf Instruments, Tujunga, CA, USA).
Immunohistochemistry. Deeply anesthetized mice were perfused with saline, followed by fixation with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were post-fixed overnight in paraformaldehyde followed by cryoprotection with 30% sucrose (pH 7.4) until brains permeated. Serial coronal sections were prepared using a cryostat microtome (Leica, Wetzlar, Germany) and directly mounted onto glass slides. Sections were incubated at room temperature with 120% normal donkey serum in phosphate-buffered saline containing 0.4% Triton X-100 for 12 h, followed by incubation with the primary antibody (phosphor-Akt (T308), TRAF6, GADD34 (1 : 1000) cell signaling) overnight at 4 1C. Sections were then washed and incubated with the appropriate Alexa Fluor-tagged secondary antibody. Omission of primary antibody served as a negative control.
Confocal microscopy. Immunofluorescence was determined using a LSM 510 Meta confocal laser microscope (Carl Zeiss, Thornwood, NY, USA), as described previously. 41 Cellular co-localization was determined in Z-stack mode using 63X oil immersion Neofluor objective (NA 12.3) with the image size set at 512 Â 512 pixels. The following excitation lasers/emission filters settings were used for various chromophores: argon2 laser was used for Alexa Fluor 488, with excitation maxima at 490 nm and emission in the range 505-530 nm. A HeNe1 laser was used for Alexa Fluor 594 with excitation maxima at 543 nm and emission in the range 568-615 nm. Z-stacks (20 optical slices) were collected at optimal pinhole diameter at 12-bit pixel depth and converted into three-dimensional projection images using LSM 510 Meta imaging software (Carl Zeiss).
Measurement of reactive oxygen species. The determination of intracellular oxidant formation was based on the oxidation of the membranepermeable probe 5-(6)-chloromethyl-2V,7V -dichlorodihydrofluorescein diacetate (CM-H2 DCFDA) (Molecular Probes, Eugene, OR, USA) to yield an intracellular-trapped fluorescent compound whose emissions at 530 nm can be captured when excited at 480 nm as described previously. 43 Brain segments were obtained from control and TBI mice, embedded in tissue freezing medium (TBS, Fisher, Pittsburg, PA, USA), frozen, cut into 30-A-m-thick sections and placed on glass slides. The sections were exposed to 10 Amol/l CM-H2 DCFDA in Krebs/ HEPES buffer and slides were incubated in a light-protected humidified chamber at 37C for 30 min. Fluorescence was then observed using Zeiss confocal microscope software (Carl Zeiss).
Measurement of NMDA-induced neurotoxicity in primary neurons. To activate NMDA receptors in neurons, 8-to 10-day-old cultures (DIC 8-10) were treated with Mg2 þ À free Earle's balanced salt solution containing 300 mM NMDA and 5 mM glycine for 10 min as described previously. 40 Three days before NMDA receptor activation, cerebellar granule neurons were transfected with plasmids as follows: after preincubation of cells with neurobasal media (GIBCO BRL, Life Technologies, Grand Island, NY, USA), including B27 for 24 h from DIV 5, neurons were transfected with 1 mg of RNAi of either control, TRAF6 or GADD34 (Santa Cruz) and a total of 3 mg of varied combinations of plasmids using Lipofectamine 2000. Using confocal microscopy with a digital camera, we captured images of more than 20 fields per preparation, which were randomly chosen in a blind manner. GFP-positive neurons were tallied in each field and added together to determine the percentage of viable cells compared with control.
Three days before NMDA receptor activation, RNAi lentivirus was infected into cortical neurons. Viability of neurons was assayed 12 or 24 h after exposure to NMDA as follows: cells were washed with PBS and incubated in 1 mg/ml propidium iodide for 10 min (dead cells are stained in red). After extensive washing to remove nonspecifically attached propidium iodide to cell debris by PBS, neurons were then fixed in 4% paraformaldehyde in PBS and stained with DAPI to visualize the total cell population. As the majority of neurons were infected, the ratio of propidium iodide-stained cells to DAPI-stained cells was employed to reflect toxicity.
Western blotting. Whole-tissue lysates were prepared from 3-mm coronal sections centered upon the site of impact. A 1-mm micropunch was collected from the pericontusional cortex or from the corresponding contralateral hemisphere as described previously. 41, 42 Tissue was placed in complete RIPA buffer, sonicated, and centrifuged for 120 min at 124 000 Â g at 4 1C. Thirty micrograms of protein were resolved on a 4-20% SDS-polyacrylamide gel and transferred onto a polyvinylidene difluoride membrane. Blots were incubated overnight at 4 1C in primary antibody Akt, phosphorylated-Akt (T308), phosphorylated-Akt (S473), GADD34, ATF4, phosphor-PERK, phosphor-eIF2alpha (1 : 1000; Cell Signaling, Danvers, MA, USA) followed by a 2 h incubation with an Alexa Fluor-tagged secondary antibody at room temperature, per our laboratory. Blots were visualized using a Li-Cor Odyssey near-infrared imaging system and densitometry analysis was performed using Quantity One software (Bio-Rad, Foster City, CA, USA).
Statistical analysis. The effects of treatments were analyzed using a one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test. Results are expressed as mean ± S.E.M. A P-value o0.05 was considered to be statistically significant.
Conflict of Interest
The authors declare no conflict of interest.
